Do microbiome therapies actually prevent disease recurrence long-term, or just improve lab numbers?
The strongest evidence for durable benefit comes from recurrent Clostridioides difficile infection (rCDI), where microbiome therapeutics have been tested in large, placebo-controlled trials with follow-up out to two years. In a phase 2 open-label study of RBX2660 (a rectally administered, donor-derived microbiota product), more than 90% of patients who responded at 8 weeks remained free of CDI recurrence at 6, 12, and 24 months [5]. That means the vast majority of initial responders didn't just get a temporary fix—they stayed well for two years. The gut microbiome of these patients shifted from a dysbiotic (unhealthy) state to a diverse, healthy composition within 7 days of treatment, and that restoration remained stable through the entire 24-month follow-up [5].
Similarly, SER-109, an oral capsule of purified spore-forming bacteria, was tested in a placebo-controlled trial of adults with a history of recurrent CDI. At 8 weeks, only 12% of SER-109 recipients had a recurrence, compared to 40% in the placebo group—a highly significant difference [2]. While 8 weeks is shorter than two years, the magnitude of the reduction (nearly 70% relative risk reduction) and the fact that it was measured against a placebo control makes this a robust finding. The paper also notes that compositional and functional changes in the gut microbiome after SER-109 treatment were 'critical to a sustained clinical response' [2], linking the microbial change directly to the clinical outcome.
These results converge: across different products and delivery methods, microbiome therapeutics for rCDI produce durable, clinically meaningful benefits that go well beyond short-term biomarker changes. The key mechanism is restoration of colonization resistance—the ability of a healthy microbial community to prevent C. difficile from overgrowing—which is a functional, long-lasting change, not a temporary lab shift.
Does the evidence extend to other diseases like liver disease?
Yes, but the evidence is earlier-stage and more mixed than in C. diff. In liver disease, the gut-liver axis means that changes in the microbiome can directly affect liver function, inflammation, and complications like hepatic encephalopathy (HE) [3]. Several microbiome-based approaches have shown promise beyond short-term biomarkers. For example, in patients with cirrhosis and HE, fecal microbiota transplant (FMT) given by enema after antibiotics was safe in a phase 1 trial and showed 'potential improvements in cognition and hospitalizations' [3]. In another study, FMT capsules given without pre-treatment antibiotics also appeared safe and showed cognitive benefits [3].
The prebiotic lactulose, already standard for HE, works by fermenting into short-chain fatty acids that strengthen the gut barrier, reduce ammonia production, and trap ammonia in the colon for excretion—a multi-step mechanism that produces a sustained clinical benefit (fewer HE episodes) [3]. Similarly, the non-absorbable antibiotic rifaximin is effective for preventing HE recurrence, with effects linked to changes in microbial function (especially reducing ammonia-producing Streptococcus) rather than just killing bacteria [3].
However, not all microbiome interventions in liver disease have succeeded. FMT for nonalcoholic steatohepatitis (NASH) has been 'largely unsuccessful in meaningfully changing clinical outcomes' [3]. Probiotics in chronic liver disease have a 'mixed record' and current evidence 'does not point toward meaningful changes in clinically relevant outcomes' [3]. This contrast is instructive: the strongest evidence for durable benefit comes from conditions where the microbiome is the primary driver (like rCDI), while in complex metabolic diseases, the microbiome is one of many factors, making it harder to produce a large, sustained clinical effect.
How do these therapies produce lasting change, and what are the limitations?
The core mechanism is ecological restoration. In rCDI, antibiotics wipe out protective gut bacteria, allowing C. difficile to flourish. Microbiome therapeutics reintroduce a diverse community of beneficial bacteria that physically occupy the niche, produce antimicrobial compounds, and restore bile acid metabolism—all of which suppress C. difficile [1][2]. This is not a drug that gets metabolized and cleared; it's a living ecosystem that, if it engrafts, can sustain itself. The RBX2660 data show that the restored microbiome remained stable for 24 months [5], and the VE303 consortium (8 defined Clostridia strains) produced a dose-dependent reduction in recurrence, with high-dose VE303 achieving 13.8% recurrence vs. 36.4% with placebo [1].
However, there are important caveats. First, not all products succeed: the development of CP101 (a donor-derived product) was discontinued after a phase 3 trial [1], and MET-2 (a 40-species consortium) was also halted despite showing efficacy, because the competitive landscape made further development unviable [1]. Second, safety concerns remain—there have been reports of FMT transmitting drug-resistant E. coli bacteremia to a patient with cirrhosis [3], and donor-derived products carry risks of pathogen transmission, which is why regulators are pushing for well-defined, donor-independent products [1]. Third, the evidence is strongest for rCDI; for other conditions like liver disease, the field is still in early phases, with many small trials and mixed results [3].
The bottom line: microbiome therapeutics can produce durable, clinically meaningful improvements in health, but the strength of evidence varies dramatically by condition. For recurrent C. diff, the data are robust and show long-term benefit. For liver disease and other conditions, the potential is real but unproven, and larger, rigorous trials are needed [3].
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2023, 5 in Q1 journals, collectively cited 2,726 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 53 papers retrieved from a database of over 500 million.
Sources used in this answer
Future Microbiome Therapeutics for Clostridioides difficile Infection
Reviews multiple live biotherapeutic products (LBPs) for recurrent C. diff, including VE303 (8-strain consortium) which in a phase 2 trial reduced recurrence to 13.8% vs. 36.4% with placebo, and NTCD-M3 (nontoxigenic C. difficile) which achieved only 5% recurrence vs. 30% placebo in a phase 2b trial. Also notes that development of CP101 and MET-2 was discontinued despite efficacy, highlighting challenges in the competitive space.
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
In a placebo-controlled trial of SER-109 (oral spore-based microbiome therapeutic) for recurrent C. diff, recurrence at 8 weeks was 12% vs. 40% with placebo (p < 0.001). The paper emphasizes that compositional and functional microbiome changes after treatment are critical to sustained clinical response.
The Current and Future State of Microbiome Therapeutics in Liver Disease
Reviews microbiome therapeutics in liver disease, including FMT for hepatic encephalopathy showing potential improvements in cognition and hospitalizations in phase 1/2 trials, lactulose and rifaximin as established therapies, and notes that FMT for NASH has been largely unsuccessful. Highlights that defined bacterial consortia and bacteriophages are promising but need larger trials.
Microbiota in health and diseases
Broad review of microbiota in health and disease, covering gut-brain axis, colonization resistance, immune modulation, and clinical approaches including microbiota modulation and FMT. Does not provide specific quantitative outcomes for any single therapeutic.
The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
In a phase 2 open-label study of RBX2660 (rectal microbiota-based LBP) for recurrent C. diff, over 90% of initial responders remained CDI-free at 6, 12, and 24 months. Microbiome restoration occurred within 7 days and remained stable through 24 months. No new safety concerns emerged during long-term follow-up.